← Leaderboards
Steven Treon
Dana-Farber Cancer Institute
$2,723,565
Attributed
$2,723,565
Total exposure
2
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $471.3K · FY2019–23$500K$375K$250K$125K$0
'19
'20
'21
'22
'23
Funding mix
By agency
NIH$2,723,565 · 2
By mechanism
P50$2,090,010 · 1
K23$633,555 · 1
Top collaborators
No co-investigators on record.
Most similar at Dana-Farber Cancer Institute
Same institution · by research overlap
- Margaret A Shipp$7,796,368
- Ruben D Carrasco$9,710,954
- Hanna Katri Annikki Mikkola$9,035,936
- Jennifer R Brown$9,365,864
- Evan D Rosen$31,513,156
Others in their field
Top investigators on “Multiple Myeloma”
- David Heimbrook · Leidos Biomedical Research, Inc.$146,380,351
- Larry Arthur$41,717,333
- Charles A Coltman · Southwest Oncology Group$36,988,659
- Kenneth C Anderson · Dana-Farber Cancer Inst$25,497,347
- Irene M. Ghobrial · Dana-Farber Cancer Inst$22,402,686
- Nilsa Del Carmen Ramirez · Ohio State University$22,287,552
Research focus
Multiple MyelomaAntitumor AntibodyCellular EngineeringAnalogBindingB-LymphocytesCd AntigensApoptosisCell GrowthCell KillingCell LineCell OntogenyCellsCell SurvivalAgammaglobulinaemia Tyrosine KinaseClinical ResearchCell Adhesion MoleculesClinical TrialsCytokineCytotoxicDependenceDrug ApprovalDrug DevelopmentEngineering
Grant awards (10)
Targeting mutated MYD88 signaling in WM$399,585
P50 · FY2023 · CA · contact PI
Targeting mutated MYD88 signaling in WM$399,585
P50 · FY2022 · CA · contact PI
Targeting mutated MYD88 signaling in WM$471,278
P50 · FY2021 · CA · contact PI
Targeting mutated MYD88 signaling in WM$419,976
P50 · FY2020 · CA · contact PI
Targeting mutated MYD88 signaling in WM$399,586
P50 · FY2019 · CA · contact PI
NOVEL SEROTHERAPY STRATEGIES--PLASMA CELL MALIGNANCIES$126,711
K23 · FY2004 · CA
NOVEL SEROTHERAPY STRATEGIES--PLASMA CELL MALIGNANCIES$126,711
K23 · FY2003 · CA
NOVEL SEROTHERAPY STRATEGIES--PLASMA CELL MALIGNANCIES$126,711
K23 · FY2002 · CA
NOVEL SEROTHERAPY STRATEGIES--PLASMA CELL MALIGNANCIES$126,711
K23 · FY2001 · CA
NOVEL SEROTHERAPY STRATEGIES--PLASMA CELL MALIGNANCIES$126,711
K23 · FY2000 · CA